Levosimendan

Indian Pediatrics

Volumn 46, Issue 7, 2009, Pages 593-596

  Kamath, Shrishu R ^a   Jaykumar, Indira ^b   Matha, Sunit ^b  

^a Waterford Apartments   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; MILRINONE;

CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; HALF LIFE TIME; HEADACHE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INOTROPISM; LOADING DRUG DOSE; PHARMACOLOGY; REVIEW;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 67650432937     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Marino P, Sutin KM. Acute heart failure syndromes. Chapter 14. The ICU Book. 3rd Edition. Philadelphia. Lippincott Williams and Wilkins Publications; 2006. p. 265.
2. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001; 61: 613-627.
3. Remme WJ, Swedberg K and the Task Force for the Diagnosis and Treatment of Chronic Heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
4. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with Levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med 2006; 7: 445-448. (Pubitemid 44386070)
5. Egan JR, Clarke AJ, Williams S, Cole AD, Ayer J, Jacobe S, et al. Levosimendan for low cardiac output: A Pediatric experience. J Intensive Care Med 2006; 21:.183-187.
6. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5: 457-462.
7. Lechner E, Moosbauer W, Pinter M, Mair R, Tulzer G. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate. Pediatr Crit Care Med. 2007; 8: 61-63. (Pubitemid 46168361)
8. Braun JP, Jasulaitis D, Moshirzadeh M, Doepfmer UR, Kastrup M, von Heymann C, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for postcardiotomy heart failure. Crit Care 2006;10: R17. (Pubitemid 47079804)
9. Garratt C, Packer M, Colucci W, Fisher L, Massie B, Teerlink J, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE I study. Crit Care 2004; 8: P89.
10. Mebazaa A, Nieminen M, Packer M, Cohen-Salal A, Kleber F, Pocock S, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883-1891.
11. Follath F, Cleland JG, Just H, Papp JG, Schoolz H, Peuhkurinen K, et al.; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
12. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebriket LB, et al; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432. (Pubitemid 36285574)
13. Zairis MN, Apostolatos C, Anastasiadis P, Mytas D, Katsaris C, Kouris N, et al. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results drom the calcium sensitizer or inotrope or none in low output heart failure study (CASINO). Program and abstracts from the American College of Cardiology Annual Scientific Sessions 2004; March 7-10, 2004; New Orleans, Louisiana. Abstract 835-6
14. Andrea M, Jean-Louis T, Maurizio S, Baron VA, Rocco H, Conti G, et al. Effects of Leosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006; 34: 2287-2293. (Pubitemid 44260011)
15. Noto A, Giacomini M, Palandi A, Stabile L, Reali- Forster C, Iapichano G, et al. Levosimendan in septic cardiac failure. Intensive Care Med 2005; 31: 164-165.
16. Brierley J, Choong K, Cornell T, DeCaen A, Deymann A, Doctor A, et al. 2007 American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2009; 37: 1-23.
17. Harjola V-P, Peuhkurinen K, Nieminen MS, Niemala M, Sunderberg G. Oral levosimendan improves cardiac function and hemodynamicsin patients with severe congestive heart failure. Am J Cardiol 1999; 83: 4I-8I. (Pubitemid 29334909)
18. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 2004; 44: 1143-1150. (Pubitemid 39206318)
19. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, et al. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 2003; 41: 365-373. (Pubitemid 36975197)